# Mounjaro (tirzepatide)

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/mounjaro-tirzepatide
Canonical HTML page: https://getyourbrief.com/entity/mounjaro-tirzepatide

## Timeline

- **2026-07-21**: Lawsuit Filed — Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.
- **2026-07-21**: Lawsuit Filed — Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.
- **2026-03**: FDA Approves Wegovy 7.2 mg — Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.
- **2026-03**: FDA Approves Wegovy 7.2 mg — Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.

## Recent coverage (4 stories, network-wide)

### Oncology, diabetes drive Indian pharma; Mounjaro sales up 880% to ₹1,228 Cr
2026-08-09 18:00:54 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Indian pharmaceutical market expanded 12.1% by value in July 2026, but unit growth inched up only 1.6%, revealing a market shifting to high-value, specialty therapies. Anti-neoplastics and anti-diabetics led therapy-area growth, while Eli Lilly’s Mounjaro captured more than half of the diabetes segment with an 880% sales surge. For biotech and pharma firms, the data underscores the imperative to invest in innovation and patient access strategies.
Full story: https://getbiobrief.com/story/indian-pharma-market-growth-july-2026-bio

### Wegovy 7.2 mg Shows 19% Weight Loss; Novo Sues Lilly Over Patient Misinformation
2026-07-21 14:14:59 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 3

The suit ensures obesity patients receive the latest efficacy data, as Novo contends Lilly’s ads deny consumers a full picture of treatment options, potentially swaying prescriptions.
Full story: https://gethealthbrief.com/story/novo-lilly-glp1-lawsuit-patient-data

### STEP UP Trial’s 19% Weight Loss Underpins Novo’s Suit Against Lilly’s GLP-1 Ads
2026-07-21 14:14:48 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 3

The litigation underscores the GLP-1 dosing race: Wegovy 7.2 mg’s clinical superiority reshapes head-to-head comparisons, forcing Lilly to legally defend its ad strategy amid rapid innovation.
Full story: https://getbiobrief.com/story/novo-lilly-glp1-lawsuit-stepup-clinical-data

### Novo Sues Lilly: Omits Wegovy’s 19% Weight Loss, Seeks Injunction
2026-07-21 14:14:08 · Sector: legal · Sentiment: Neutral · Impact: 7/10 · Sources: 3

Novo Nordisk alleges Lanham Act violations; case tests whether outdated comparisons in DTC ads constitute false advertising, with potential precedent for pharma.
Full story: https://getlegalbrief.com/story/novo-sues-lilly-false-advertising-glp1-injunction

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.